Supernus Pharmaceuticals, Inc. (SUPN) CFO Gregory S. Patrick Sells 50,000 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 48.20 on Tuesday. The stock has a market capitalization of $2.44 billion, a P/E ratio of 24.32 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $49.95. The firm’s 50-day moving average is $43.55 and its 200-day moving average is $36.98.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The firm had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. Analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) CFO Gregory S. Patrick Sells 50,000 Shares of Stock” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/09/12/supernus-pharmaceuticals-inc-supn-cfo-gregory-s-patrick-sells-50000-shares-of-stock.html.

Several large investors have recently modified their holdings of the company. Meeder Asset Management Inc. increased its holdings in Supernus Pharmaceuticals by 3,455.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in Supernus Pharmaceuticals in the 1st quarter worth about $127,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,462 shares in the last quarter. Finally, Advisor Group Inc. increased its holdings in Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares in the last quarter. Hedge funds and other institutional investors own 95.38% of the company’s stock.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Thursday, July 13th. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 5th. Jefferies Group LLC lifted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $48.29.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply